Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

Menu

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
My View
Tags:
Companies Strategy Neurology

BIO-Europe Spring 2019: Addex CEO: There’s Space For Better Therapies In Parkinson’s

Executive Summary

At the recent BIO-Europe Spring partnering conference, Tim Dyer, CEO of Addex Therapeutics, spoke to Lucie Ellis, executive editor of In Vivo, about the company’s small-molecule allosteric modulators for central nervous system disorders.

At the event in Vienna, Austria, Addex Therapeutics CEO Tim Dyer discussed the company’s pipeline and strategy within the high-risk CNS landscape. Addex’s lead compound, dipraglurant, is being developed as a treatment for Parkinson’s disease levodopa-induced dyskinesia. Dyer talked about moving the drug into Phase III trials and preparing for commercial success. 


Open Media
Table

View full table

Topics

Related Companies

Tags:
Companies Strategy Neurology
Latest Headlines

Xaira Launches With $1bn-Plus And End-To-End AI Strategy

Biogen Sees Improving Momentum In Slow Leqembi Launch

Cidara Offloads Rezzayo, Will Focus On Universal Flu Preventative

Day One Springs Into Commercial Action With Ojemda Approval

See All
UsernamePublicRestriction

Register

SC125057

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By